Australian pharma patentees now face an uphill battle to obtain interlocutory injunctions
Shutterstock/ChameleonsEye
The tide has turned against rights holders in recent years, write Gavin Adkins and Jacqueline Simpkin of Griffith Hack – though an accompanying trend of expedited trials offers some consolation
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now